Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 6/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.32 |
| ▸ | KHK | P50053 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4596732 | 1.00 | SLC18A3 (0.36) | SLC18A3SIGMAR1HTR2CBRD4SMN1; SMN2 | |
| SCHEMBL4598197 | 0.82 | SLC18A3 (0.38) | SLC18A3SIGMAR1HTR2CBRD4SMN1; SMN2 | |
| SCHEMBL4598200 | 0.82 | SLC18A3 (0.38) | SLC18A3SIGMAR1HTR2CBRD4SMN1; SMN2 | |
| SCHEMBL4598206 | 0.82 | SLC18A3 (0.38) | SLC18A3SIGMAR1HTR2CBRD4SMN1; SMN2 | |
| SCHEMBL4597466 | 0.76 | GSK3B (0.42) | BRD4SMN1; SMN2MAPT | |
| SCHEMBL4597462 | 0.76 | GSK3B (0.42) | BRD4SMN1; SMN2MAPT | |
| SCHEMBL4597461 | 0.76 | GSK3B (0.42) | BRD4SMN1; SMN2MAPT | |
| SCHEMBL6498015 | 0.76 | SLC18A3 (0.42) | SLC18A3SIGMAR1BRD4SMN1; SMN2HPGD | |
| SCHEMBL3759045 | 0.76 | SLC18A3 (0.42) | SLC18A3SIGMAR1BRD4SMN1; SMN2HPGD | |
| SCHEMBL4597196 | 0.76 | SLC18A3 (0.42) | SLC18A3SIGMAR1HTR2CBRD4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924265-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | Genzyme Corporation (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | SLC18A3 1545/4885SIGMAR1 1177/4885HTR2C 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.